PepGen Inc.

PepGen Inc.

PEPG·NASDAQ

$1.46

+3.0%
HealthcareBiotechnology

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.

At a Glance

Live Snapshot
Market Cap$101.28M
EPS-2.1200
P/E Ratio-0.69
Earnings Date08/06/2026

pepg

Selling, General and Administrative Expenses

Last Annual Value

22.57M

3-Year CAGR

17%

5-Year CAGR

93%

10-Year CAGR

43%

PepGen Inc.

PepGen Inc. Competitors Analysis of Selling, General and Administrative Expenses

PEPG · NASDAQ
CompanySelling, General and Administrative Expenses
CAGR 3Y
CAGR 5Y
CAGR 10Y
PEPG logo
PepGen Inc.
NASDAQ:PEPG
22.57M
10.7%22.7%N/A 
ALEC logo
Alector, Inc.
NASDAQ:ALEC
53.99M
-1.6%-0.4%39.9%
NKTX logo
Nkarta, Inc.
NASDAQ:NKTX
31.57M
-3.3%6.5%N/A
56.01M
39.5%5.4%N/A
12.20M
55.2%N/AN/A
20.75M
40.3%40.8%N/A
36.20M
-4.9%1.7%N/A
9.42M
7.8%23.0%N/A
27.22M
-17.0%-11.9%N/A
68.80M
60.8%53.6%28.1%
15.21M
3.0%-5.7%8.9%
PepGen Inc.

PepGen Inc. Fair Value Envelope

PEPG · NASDAQ

Our analysis suggests that PEPG has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.4642, this represents a potential HIDDEN relative to our calculated worth for PepGen Inc..

Intrinsic Value
Current Price: $1.4642